Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Benevolo

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Leukemia|May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyTiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Leukemia|May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyTiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Pageof 13